Beraldi E - Search Results

1

The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.

Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM. Jackson JK, et al. Among authors: beraldi e. Cancer Res. 2000 Aug 1;60(15):4146-51. Cancer Res. 2000. PMID: 10945622

2

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.

Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M. Rocchi P, et al. Among authors: beraldi e. Cancer Res. 2004 Sep 15;64(18):6595-602. doi: 10.1158/0008-5472.CAN-03-3998. Cancer Res. 2004. PMID: 15374973

3

Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.

Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M. Rocchi P, et al. Among authors: beraldi e. Cancer Res. 2005 Dec 1;65(23):11083-93. doi: 10.1158/0008-5472.CAN-05-1840. Cancer Res. 2005. PMID: 16322258

4

A polymeric paste-drug formulation for intratumoral treatment of prostate cancer.

Kesch C, Schmitt V, Bidnur S, Thi M, Beraldi E, Moskalev I, Yago V, Bowden M, Adomat H, Fazil L, Jackson JK, Gleave ME. Kesch C, et al. Among authors: beraldi e. Prostate Cancer Prostatic Dis. 2020 Jun;23(2):324-332. doi: 10.1038/s41391-019-0190-x. Epub 2019 Nov 25. Prostate Cancer Prostatic Dis. 2020. PMID: 31767941

5

A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. Sato N, et al. Among authors: beraldi e. Cancer Res. 1997 Apr 15;57(8):1584-9. Cancer Res. 1997. PMID: 9108464

6

Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.

Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J. Gleave M, et al. Among authors: beraldi e. Clin Cancer Res. 1999 Oct;5(10):2891-8. Clin Cancer Res. 1999. PMID: 10537358

7

Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.

July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME. July LV, et al. Among authors: beraldi e. Mol Cancer Ther. 2004 Mar;3(3):223-32. Mol Cancer Ther. 2004. PMID: 15026542

8

Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells.

Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M. Kamada M, et al. Among authors: beraldi e. Mol Cancer Ther. 2007 Jan;6(1):299-308. doi: 10.1158/1535-7163.MCT-06-0417. Epub 2007 Jan 11. Mol Cancer Ther. 2007. PMID: 17218637

9

Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity.

Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M. Zoubeidi A, et al. Among authors: beraldi e. Cancer Res. 2007 Nov 1;67(21):10455-65. doi: 10.1158/0008-5472.CAN-07-2057. Cancer Res. 2007. PMID: 17974989 Free article.

10

Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells.

Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LW, Nelson CC, Rennie PS, Gleave ME. Zoubeidi A, et al. Among authors: beraldi e. Mol Cancer Res. 2010 Jan;8(1):119-30. doi: 10.1158/1541-7786.MCR-09-0277. Epub 2010 Jan 12. Mol Cancer Res. 2010. PMID: 20068069 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Search Page

Filters